International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort (DOI:10.1016/j.surg.2006.06.009);International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: Analysis of efficacy and safety data in a large surgical cohort

Surgery

Volumn 140, Issue 5, 2006, Pages 726-739

  Payen, Didier ^a   Sablotzki, Armin ^a   Barie, Philip S ^a   Ramsay, Graham ^a   Lowry, Stephen ^a   Williams, Mark ^a   Sarwat, Samiha ^a   Northrup, Justin ^a   Toland, Patricia ^a   McL Booth, Frank V ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; PLACEBO;

ADULT; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MORTALITY; MULTIPLE ORGAN FAILURE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPSIS; SURGICAL PATIENT; SURGICAL RISK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33751062371     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.02.004     Document Type: Erratum

References (41)

1. Merlino J.I., Yowler C.J., and Malangoni M.A. Nosocomial infections adversely affect the outcomes of patients with serious intra-abdominal infections. Surg Infect 5 (2004) 21-27
2. Garrison R.N., Spain D.A., Wilson M.A., Keelen P.A., and Harris P.D. Microvascular changes explain the "two-hit" theory of multiple organ failure. Ann Surg 227 (1998) 851-860
3. Bernard G.R., Vincent J.L., Laterre P.F., LaRosa S.P., Dhainaut J.F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
4. Bernard G.R., Margolis B.D., Shanies H.M., Ely E.W., Wheeler A.P., Levy H., et al. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Chest 125 (2004) 2206-2216
5. Barie P.S., Williams M.D., McCollam J.S., Bates B.M., Qualy R.L., Lowry S.F., et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. Am J Surg 188 (2004) 212-220
6. Joyce D.E., and Grinnell B.W. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 30 suppl (2002) S288-S293
7. Dhainaut J.F., Yan S.B., Margolis B.D., Lorente J.A., Russell J.A., Freebairn R.C., et al. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 90 (2003) 642-653
8. Derhaschnig U., Reiter R., Knobl P., Baumgartner M., Keen P., and Jilma B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 102 (2003) 2093-2098
9. Kalil A.C., Coyle S.M., Um J.Y., LaRosa S.P., Turlo M.A., Calvano S.E., et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 21 (2004) 222-229
10. Nick J.A., Coldren C.D., Geraci M.W., Poch K.R., Fouty B.W., O'Brien J., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104 (2004) 3878-3885 [Erratum in Blood 2005;105:3785.]
11. Fry D.E., Beilman G., Johnson S., Williams M.D., Rodman G., Booth F.V., et al. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. Surg Infect 5 (2004) 253-259
12. Knaus W.A., Draper E.A., Wagner D.P., and Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 13 (1985) 818-829
13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20 (1992) 864-874
14. Vincent J.L., Moreno R., Takala J., Willatts S., DeMendonca A., Bruining H., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (1996) 707-710
15. Abraham E., Naum C., Bandi V., Gervich D., Lowry S.F., Wunderink R., et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med 31 (2003) 718-728
16. Bernard G.R., Ely E.W., Wright T.J., Fraiz J., Stasek Jr. J.E., Russell J.A., et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 29 (2001) 2051-2059
17. Vincent J.L., Bernard G.R., Beale R., Doig C., Putensen C., Dhainaut J.F., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266-2277
18. Zeiher B.G., Steingrub J., Laterre P.F., Dmitrienko A., Fukishi Y., Abraham E., and EZZI Study Group. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care 33 (2005) 1741-1748
19. Brown E.G., Wood L., and Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999) 109-117
20. Brown E.G. Methods and pitfalls in searching drug safety databases utilizing the Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf 26 (2003) 145-158
21. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17 (1998) 2265-2281
22. Joffe M.M., and Rosenbaum P.R. Invited commentary: propensity scores. Am J Epidemiol 150 (1999) 327-333
23. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
24. Sashegyi A., Trzaskoma B.L., Nelson D.R., Williams M.D., and Macias W.L. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH. Curr Med Res Opin 22 (2006) 1001-1012
25. Assmann S.F., Pocock S.J., Enos L.E., and Kasten L.E. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 (2000) 1064-1069
26. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 14 (1982) 473-482
27. Angus D.C., Linde-Zwirble W.T., Clermont G., Ball D.E., Basson B.R., Ely E.W., et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31 (2003) 1-11
28. Manns B.J., Lee H., Doig C.J., Johnson D., and Donaldson C. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347 (2002) 993-1000
29. Macias W.L., and Nelson D.R. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32 suppl (2004) S223-S228
30. Guller U., and DeLong E.R. Interpreting statistics in medical literature: a vade mecum for surgeons. J Am Coll Surg 198 (2004) 441-458
31. Abraham E., Laterre P.F., Gang R., Levy H., Talwar D., Trzaskoma B.L., et al. Efficacy and safety of Drotrecogin alfa (activated) in adult severe sepsis patients at low risk of death. N Engl J Med 353 (2005) 1332-1341
32. Vincent J.L., Abraham E., Annane D., Bernard G., Rivers E., and Van den Berghe G. Reducing mortality in sepsis: new directions. Crit Care (London) 6 suppl 3 (2002) S1-S18
33. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. [Erratum in Crit Care Med 2004;32:1448. Correction of dosage error in text Crit Care Med 2004;32:2169-70.]. Crit Care Med 32 (2004) 2169-2170
34. Beilman G.J. New strategies to improve outcomes in the surgical intensive unit. Surg Infect 5 (2004) 289-300
35. Rivers E., Nguyen B., Havstad S., Ressler S., Muzzin A., Knoblich B., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368-1377
36. Pittas A.G., Siegel R.D., and Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med 164 (2004) 2005-2011
37. Fry D.E. Definitive versus temporizing therapy. In: Schein M., and Marshall J.C. (Eds). Source control: a guide to the management of surgical infections (2003), Springer-Verlag, New York 53-61
38. Levi M., and Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 341 (1999) 586-592
39. Levi M., de Jonge E., and van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 16 (2003) 43-47
40. Talmor M., Hydo L., and Barie P.S. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: effect of intensive care unit resuscitation. Arch Surg 134 (1999) 81-87
41. Dhainaut J.F., Yan S.B., Joyce D.E., Pettila V., Basson B., Brandt J.T., et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2 (2004) 1924-1933